Global and gene-specific promoter methylation analysis in primary hyperparathyroidism

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Primary hyperparathyroidism pathogenesis is poorly understood.
• Epigenetic alterations, specifically DNA promoter methylation, are implicated in tumor development.
• Limited studies exist on methylation in parathyroid tumors.

Purpose of the Study:

• To investigate the role of aberrant DNA promoter methylation in parathyroid tumor pathogenesis.
• To quantify CpG island promoter methylation density of key candidate genes.
• To correlate methylation status with gene expression and clinical features.

Main Methods:

• Bisulfite pyrosequencing of 72 parathyroid tumors and 3 normal references.
• Quantification of methylation for APC (promoter 1A and 1B), β-catenin (CTNNB1), CASR, CDC73/HRPT2, MEN1, P16 (CDKN2A), PAX1, RASSF1A, SFRP1, and VDR.
• Assessment of global methylation using LINE-1 and gene expression via qRT-PCR.

Main Results:

• Adenomas showed frequent hypermethylation of APC 1A (56%), RASSF1A (52%), and β-catenin (29%).
• Carcinomas exhibited hypermethylation of RASSF1A and SFRP1.
• Hypermethylated genes generally had reduced expression; APC 1A methylation correlated with adenoma weight.

Conclusions:

• Aberrant DNA promoter methylation of APC 1A, β-catenin, and RASSF1A is implicated in a subset of parathyroid tumors.
• Methylation patterns differ between parathyroid tumor subtypes.
• Findings contribute to understanding the epigenetic landscape of parathyroid tumorigenesis.